76. Advancing immuno-oncology, Michel Detheux, President and CEO, iTeos Therapeutics

Michel Detheux is the co-founder, President, and CEO of iTeos Therapeutics, and has held the role of CEO since the company’s inception in 2012. He previously served as a director at Ludwig Cancer Research from December 2010 to March 2012. Prior to that, Michel worked in various scientific and business development roles at Ogeda (f/k/a Euroscreen). He has also held roles concurrent to his time at iTeos, including Founder and Managing Director of MG6A Bioconsulting SPRL, Director of the Board at BioWin, and Board Member at Immune Health. He studied at Université Catholique de Louvain, receiving his undergraduate degree and his PhD in biochemistry there, before doing his post-doc in parasitology at University of Glasgow and receiving a business certificate from Solvay Brussels School. Michel holds a degree in biochemistry and a Ph.D. in Biochemistry from Université Catholique de Louvain and a business certificate from Solvay Business School.